The AASK Cohort Study

AASK 队列研究

• 批准号: 6937099
• 负责人: WILLIAM H CLEVELAND
• 金额: $ 2.89万
• 依托单位: MOREHOUSE SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-29 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6937099
• 关键词: ACE inhibitors; African American; antihypertensive agents; blood chemistry; blood pressure; cardiovascular disorder; cardiovascular disorder chemotherapy; chronic renal failure; clinical research; comorbidity; cooperative study; creatinine; data collection methodology /evaluation; disease /disorder proneness /risk; echocardiography; human subject; human therapy evaluation; kidney function; outcomes research; patient oriented research; questionnaires; renal hypertension; sample collection

DESCRIPTION (provided by applicant): Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.

描述（由申请人提供）： 高血压肾脏疾病通常会进展。 AASK（非裔美国人研究肾脏疾病和高血压研究）研究的主要目标是确定肾功能和肾脏疾病进展的危险因素的进展，患有高血压肾脏疾病的肾脏疾病进展，这些肾脏疾病接受了推荐的抗高血压治疗。次要目标是确定心血管疾病的发生并评估其危险因素。 AASK队列研究是一项前瞻性，观察性研究，是AASK试验的扩展。 AASK试验测试了3种用作初始降压治疗（Ramipril，Metoprolol和amlodipine）和2级水平的血压控制的药物的作用。在1,094名试验参与者中，大约有650至700名尚未达到末期肾脏疾病（ESRD）的人可能会参加研究。要研究的危险因素包括环境，遗传，生理和社会经济变量。主要的肾脏结果是由血清肌酐，ESRD或死亡增加一倍的综合临床结果。从血管紧张素转化酶抑制剂Ramipril开始，为所有参与者提供了用于高血压的药物治疗。以这种方式，该研究直接控制了肾脏疾病进展的两个主要决定因素（高血压治疗和肾脏保护性，降压药）。队列研究中的最小随访持续时间为5年（总计9至12年，包括AASK试验期间）。 最终，来自AASK队列研究的数据应增强我们对决定肾脏疾病进展的风险因素和过程的理解。这样的结果最终可能会导致新的策略延迟或阻止ESRD。